Roche and Molecular Partners AG today announced that they have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners’ DARPin ® biologics conjugated to toxic agents developed at Roche for the treatment of cancer.
As part of the realignment, Harvard Bioscience will reduce its global workforce by approximately...
The company reported that Novartis wants to use one of its injectable drug delivery systems with...
The Medicines Company paid Rempex equity holders $140 million in an upfront payment at the...
JHL Biotech, Inc., a provider of biopharmaceutical process development and manufacturing services, and Switzerland-based Selexis SA, a provider of technologies for mammalian cell line development, announced today that they have signed a non-exclusive strategic agreement to provide biopharmaceutical customers a seamless solution for the development and cGMP manufacturing of biologic drugs.
Zogenix, Inc. and Battelle have entered into a new long-term collaborative agreement regarding co-marketing of Zogenix's DosePro(R) needle-free drug delivery technology, advancing potential out-licensing opportunities for DosePro with biopharmaceutical clients, and expanding the application of the technology to higher-dose biologic therapies.
President Barack Obama announced a new initiative at the National Institutes of Health in pursuit of a cure for HIV, saying his administration is redirecting $100 million into the project to find a new generation of therapies.
Forest Laboratories says it plans to cut about 500 jobs as part of a plan to trim $500 million in costs over the next two years. The company also plans to buy back at least $400 million in company stock and agreed to pay $240 million for the U.S. marketing rights to Saphris.
Under the terms of the agreement, Forest will make an upfront payment of $240 million and additional payments to Merck based on defined sales milestones. Merck will remain responsible for product supply. Forest will assume responsibility for continued commercialization, including completing certain post marketing studies of Saphris following a transition period.
A class action suit by Australian and New Zealand victims of Thalidomide against the anti-morning sickness drug's British distributor Diageo Scotland Ltd. has been settled for 89 million Australian dollars ($81 million), a lawyer said on Monday.
Companies are bracing for an influx of participants in their insurance plans due to the health-care overhaul.
New York officials say a $5.8 million grant and up to $6.2 million in tax credits have figured into Bausch & Lomb's decision to expand manufacturing and distribution in Rochester, N.Y. Gov. Andrew Cuomo says Valeant Pharmaceutical International will invest $106 million to expand capacity for its subsidiary's new line of contact lenses.
Genomic Health and ALMAC GROUP have announced that Genomic Health will exclusively license Almac Group's technology and intellectual property to further develop, validate and subsequently commercialize a multi-gene test to predict benefit from DNA damage-based chemotherapy drugs, such as the commonly used anthracycline-based regimens, in breast cancer.
Norway-based cancer drug maker Algeta ASA says it has received a preliminary takeover offer from Germany's Bayer AG that values the company at about $2.4 billion. Algeta said in a statement Tuesday that the offer is for 336 kroner ($55.11) per share; the company has nearly 44 million shares.
Cubist Pharmaceuticals Inc. shares jumped Monday after the company said that a study of its drug for treatment of complicated urinary tract infections met its goal of showing that it works as well as existing antibiotic, levofloxacin.
Shares of troubled drugmaker Amarin fell again Friday after the Food and Drug Administration refused to reconsider a recent decision that casts doubt on the future of the company's lead product.
Swiss voters soundly rejected on Sunday a proposal to limit the pay of companies' highest-paid managers to 12 times that of their lowest-paid workers. Switzerland is home to global business players such as pharmaceutical companies Novartis and Roche; insurance groups Zurich and Swiss Re; and banks UBS and Credit Suisse.
Simulations Plus, Inc., today announced that Ms. Momoko Beran has notified the board of directors of her plan to retire effective as of January 15, 2014.
Twenty-five pharmaceutical companies will pay the state $88 million to resolve allegations they charged Louisiana's Medicaid program too much for their drugs, the final settlement reached in a 2010 lawsuit filed by Attorney General Buddy Caldwell.
Actavis has cut about 350 U.S. sales jobs since its purchase of Warner Chilcott closed in October. Actavis said it has restructured its U.S. specialty brands unit. There are now about 750 sales representatives and managers in the division.
Pfizer Inc. says it will close one of its three manufacturing plants in Puerto Rico by 2017. The world's largest drug maker says the manufacturing of products at its plant in the north coastal city of Barceloneta will be moved elsewhere.
Vertex Pharmaceuticals Inc. is selling its product royalty rights for the hepatitis C treatment Incivo for $152 million to Johnson & Johnson subsidiary Janssen Pharmaceutica. Vertex said Wednesday that Janssen will make the cash payment in the fourth quarter and then stop paying royalties in...
Juan Ramón Alaix, CEO of Zoetis, on why he's bullish on animal health and how he built a mostly female executive team.
Biopharm GmbH, Heidelberg, announced today that they have signed an agreement with Merck to cooperate with Merck Serono, the biopharmaceutical division of Merck in their research activities directed toward the molecular engineering of a biologic compound for the treatment of osteoarthritis.
Clovis Oncology has bought privately held Italian biopharmaceutical company Ethical Oncology Science SpA, gaining the U.S. marketing rights to a cancer drug the company is developing. Clovis said it is paying $200 million upfront. That includes $10 million in cash and $190 million in stock, or 3.7 million shares.
Growth in global prescription drug spending will slow to the lowest rate in decades as low-cost generic drugs continue replacing former blockbusters in the U.S. and Europe, where governments face new pressure to reduce health care spending, according to a new forecast.
Horizon Pharma will spend $35 million to acquire U.S. rights to the arthritis treatment Vimovo from AstraZeneca in a deal that the drug developer says will speed its push to profitability.
Elan says its shareholders have approved the sale of the company to Perrigo Co. for $8.6 billion. The company said 99.5 percent of the shares voted at a special meeting were voted in favor of the sale. That made up 66 percent of its total shares. Perrigo reached a deal to buy Elan Corp. PLC in a cash and stock deal in July.
Merck KGaA, Darmstadt, Germany, has announced an € 80 million investment in a new pharmaceutical manufacturing facility, to be located in the Nantong Economical Technological Development Area (NETDA), in the Greater Shanghai region (Yangtze River Delta area).
- Page 1